VIB Department of Molecular Genetics, University of Antwerp, Antwerpen, Belgium.
Neurology. 2011 Aug 9;77(6):540-8. doi: 10.1212/WNL.0b013e318228fc70. Epub 2011 Jul 13.
Ganglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype.
We performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function.
In 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients.
With this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.
神经节苷脂诱导分化相关蛋白 1(GDAP1)突变通常与常染色体隐性遗传性腓骨肌萎缩症(ARCMT)相关;然而,在极少数情况下,它们也会导致常染色体显性遗传性腓骨肌萎缩症(ADCMT)。我们旨在研究 ADCMT 中致病杂合 GDAP1 突变的频率及其相关表型。
我们通过双向测序 GDAP1 的编码区域和外显子-内含子边界,对一大组 ADCMT 患者进行了突变分析。使用等位基因定量检测排除了内含子 GDAP1 缺失。我们通过体外实验检测线粒体形态和功能,证实了一个序列变异的致病性特征。
在 8 个遗传性运动感觉神经病(CMT)家系中,我们鉴定出 4 个致病性杂合 GDAP1 突变,其中 3 个是新的。这 3 个突变的疾病外显率降低。受影响个体的发病时间不同,从儿童早期到成年期不等。大多数患者的疾病进展缓慢,总体严重程度低于常染色体隐性 GDAP1 突变。电生理变化具有异质性,但在大多数患者中与轴索性神经病相符。
通过本研究,我们拓宽了常染色体显性 GDAP1 相关神经病的表型和遗传谱。我们表明,具有显性 GDAP1 突变的患者可能表现出明显的轴索性 CMT,但也可能只有轻微的临床和电生理异常。我们证明,基于细胞的功能检测可以可靠地用于测试未知变异的致病性。我们讨论了表型变异性和常染色体显性 GDAP1 突变的低外显率对 CMT 诊断检测和咨询的影响。